299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03925194 (ClinicalTrials.gov) | October 1, 2020 | 19/4/2019 | A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF | A Phase IIa, Randomized, Placebo-controlled, Double-blind, Cross-over Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With Cystic Fibrosis | Cystic Fibrosis, 10011762 | Drug: Anakinra | Heidelberg University | NULL | Not yet recruiting | 12 Years | N/A | All | 52 | Phase 2 | Germany |
2 | EUCTR2016-004786-80-DE (EUCTR) | 30/06/2017 | Tolerability and Efficacy of Anakinra in patients with cystic fibrosis. | A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis. - ANAKIN | Cystic fibrosis MedDRA version: 20.0;Level: LLT;Classification code 10028141;Term: Mucoviscidosis;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Ruprecht-Karls-University Heidelberg, Medical Faculty | NULL | NA | Female: yes Male: yes | 52 | Phase 2 | Germany |